We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Experimental Blood Test Could Catch Pancreatic Cancer More Quickly in High-Risk People

By LabMedica International staff writers
Posted on 15 Jan 2025

Pancreatic cancer is an aggressive and difficult-to-treat disease where malignant cells develop in the pancreas, a small organ near the stomach that produces hormones and digestive fluids. More...

This cancer is particularly challenging to diagnose because it often lacks clear early symptoms, and the few symptoms that do appear can be attributed to benign conditions. By the time it is diagnosed, the cancer cells may have spread within the pancreas or to other parts of the body, a process known as metastasis, making treatment even more complicated and resulting in poorer outcomes. Detecting pancreatic cancer early significantly improves survival, but current diagnostic tools are limited. Now, an experimental blood test for pancreatic cancer is being tested by a commercial laboratory, marking a significant step towards making this test available to patients.

The new test, developed by researchers at Van Andel Institute (Grand Rapids, MI, USA) and the University of Pittsburgh (Pittsburgh, PA, USA), detects two sugars — CA199.STRA and CA19-9 — which are produced by pancreatic cancer cells and released into the bloodstream. CA19-9 is currently the standard biomarker used to diagnose pancreatic cancer. The researchers identified CA199.STRA as another cancer biomarker and developed a technology to detect it. A recent double-blinded, peer-reviewed study published in Cancer Letters showed that this experimental test identified 71% of pancreatic cancer samples accurately in the lab, compared to just 44% by the current standard test. Additionally, the new test significantly reduced the number of false negatives while maintaining a low false positive rate, as per the recent analysis. Low rates of both false positives and false negatives are crucial, as they indicate the test's ability to correctly identify the presence or absence of cancer.

Before this new test can be used by doctors to diagnose cancer, it must undergo clinical validation. In this phase, a CLIA-accredited diagnostics laboratory will adapt the experimental test into a version that works consistently under the strict conditions of a clinical lab. CLIA is a federal standard that ensures laboratory quality. The clinical validation process is expected to take two years. If the test successfully passes clinical validation, it could be used to detect pancreatic cancer more quickly in high-risk individuals, enabling earlier treatment. The test may also be useful for monitoring the progression of the disease and evaluating treatment responses in individuals already diagnosed with pancreatic cancer.

“Validation studies are essential for transforming a test developed in an academic lab into one that is used to diagnose real people,” said VAI Professor Brian Haab, Ph.D. “For a person being evaluated for pancreatic cancer, the stakes are high. Validation studies ensure that new tests work as intended.”

Related Links:
Van Andel Institute
University of Pittsburgh


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
UHF RFID Tag & Inlay
AD-327 U9 ETSI Pure 95
New
Urine Drug Test
Instant-view® Phencyclidine Urine Drug Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.